LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...

First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc ...

Shares of Frequency Therapeutics (NASDAQ: FREQ) were crashing 74.9% as of 11:07 a.m. EDT on Tuesday. The huge drop came after the company announced disappointing top-line interim results from a phase ...

Frequency Therapeutics’ hearing loss treatment showed early signs of efficacy last year, with some patients showing improvements after a few months. Now, as the biotech plugs away at a phase 2a study, ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...

Frequency Therapeutics is going back to the drawing board. After showing promise in phase 1, four dosing regimens of its hearing loss treatment did no better than placebo in a phase 2a study. The ...

Frequency Therapeutics (NASDAQ:FREQ) stock is rocketing higher on Friday following news that it will combine with Korro Bio. This merger plan is designed to bring Korro Bio public and will focus on ...

An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...

U.S. stock futures were lower this morning, with the Dow futures falling around 300 points on Friday. Shares of Frequency Electronics, Inc. (NASDAQ:FEIM) fell sharply in today's pre-market trading ...

Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. Frequency Therapeutics has discontinued developing its remyelination program ...